EU and US could reach trade deal this weekend - Reuters
SECAUCUS, N.J. - Quest Diagnostics (NYSE:DGX), a provider of diagnostic information services with a market capitalization of $19.14 billion, has outlined a strategy aimed at driving sustainable growth and delivering long-term value to shareholders. During its 2025 Investor Day, the company’s leadership team detailed initiatives that are expected to contribute to a 4-5% compound annual growth rate (CAGR) in revenues and a 7-9% CAGR in adjusted diluted earnings per share (EPS) beyond 2025. According to InvestingPro data, Quest has demonstrated strong execution with a 6.7% revenue growth in the last twelve months and maintains a robust financial health score of 2.84 (GOOD).
The company’s Chairman, CEO, and President, Jim Davis, expressed confidence in Quest’s growth potential, citing increased market access, double-digit growth in advanced diagnostics, and strategic partnerships as key drivers. Davis also highlighted the role of continuous improvement initiatives, including investments in automation, robotics, and artificial intelligence, in enhancing quality and productivity. This strategic focus has contributed to Quest’s impressive YTD return of 14.87% and its position near its 52-week high of $178.87.
Quest Diagnostics reaffirmed its full-year 2025 guidance, with net revenues projected between $10.70 billion and $10.85 billion, and an 8.4% to 9.9% increase over the previous year. The reported diluted EPS is forecasted to range from $8.34 to $8.59, with adjusted diluted EPS between $9.55 and $9.80. The company anticipates generating approximately $1.45 billion in cash from operations and estimates capital expenditures at roughly $500 million. InvestingPro analysis reveals that Quest currently trades at a P/E ratio of 22.1x and has maintained dividend payments for 22 consecutive years, demonstrating strong shareholder commitment. For deeper insights into Quest’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
The company’s strategic priorities include expanding in the physician and hospital channels, growing in high-growth areas such as consumer-initiated testing, supporting life science partners, and leveraging data analytics. Quest also plans to generate double-digit growth from advanced diagnostics tests in key clinical areas, such as oncology and brain health.
In addition, Quest aims to achieve 3% annual productivity and cost savings through its Invigorate initiative and modernize its IT systems through Project Nova. The company intends to maintain a disciplined capital deployment strategy, returning the majority of free cash flow to shareholders and pursuing growth through strategic investments and acquisitions.
This press release contains forward-looking statements that involve risks and uncertainties, and actual results may differ materially. Non-GAAP financial measures, such as adjusted diluted EPS, are used by the company’s management for internal evaluation and are provided to assist investors and analysts in assessing Quest Diagnostics’ performance.
The information in this article is based on a press release statement from Quest Diagnostics.
In other recent news, Quest Diagnostics reported its financial results for the fourth quarter of 2024, exceeding earnings expectations with an adjusted earnings per share (EPS) of $2.23, compared to the forecasted $2.19. The company’s revenue also surpassed projections, reaching $2.62 billion against the anticipated $2.58 billion. Additionally, Quest Diagnostics announced a partnership with Google Cloud to enhance its data management and analytics capabilities using generative AI technologies. This collaboration aims to improve personalized experiences for patients and providers while maintaining data privacy and security.
In analyst updates, Citi downgraded Quest Diagnostics’ stock from Buy to Neutral, with a new price target of $185, citing concerns over margin pressures and earnings growth prospects. On the other hand, JPMorgan raised its price target for the company to $180 from the previous $173, maintaining a Neutral rating after Quest Diagnostics’ strong fourth-quarter performance. The company reported a 14.5% year-over-year increase in consolidated revenues and a 3.3% organic improvement in revenue per requisition. These developments indicate a dynamic period for Quest Diagnostics as it navigates both opportunities and challenges in the healthcare landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.